Sovaldi (sofosbuvir) — Blue Cross Blue Shield of Montana
Hepatitis C virus (HCV) infection
Preferred products
- Epclusa (sofosbuvir/velpatasvir)
 - Harvoni (ledipasvir/sofosbuvir)
 - Sovaldi (sofosbuvir)
 - Ledipasvir/Sofosbuvir
 - Sofosbuvir/Velpatasvir
 - Mavyret (glecaprevir/pibrentasvir)
 - Zepatier (elbasvir/grazoprevir)
 
Initial criteria
- Patient has FDA labeled diagnosis consistent with requested agent
 - Requested agent is FDA labeled for the patient’s genotype
 - Patient age consistent with labeling OR supported off-label age use
 - Hepatitis B viral (HBV) screening completed and appropriate monitoring in place
 - Patient has no labeled contraindications
 - Prescriber is specialist or meets AASLD simplified treatment criteria
 - If client has preferred agent(s), step therapy exception criteria met (treatment history, intolerance, contraindication, etc.)
 
Approval duration
Up to treatment duration per FDA labeling